Literature DB >> 2565212

The pharmacokinetics of albumin conjugates of D-penicillamine in rats.

D A Joyce1, D N Wade, B R Swanson.   

Abstract

A protein conjugate that forms during the metabolism of D-penicillamine (D-PEN) in rats is electrophoretically indistinguishable from the (D-PEN-albumin) mixed disulfide that forms during the oxidation of D-PEN in plasma in vitro. Both the conjugate formed in vivo and the mixed disulfide synthesized in vitro are eliminated slowly in rats, with half-lives of 5.33 +/- 0.25 days and 3.48 +/- 0.42 days, respectively. These half-lives approximate or exceed the half-lives of radioiodinated plasma protein in the animals. The stability of the D-PEN-albumin conjugate contrasts with the rapid elimination of D-PEN itself and probably explains delayed elimination of D-PEN-containing disulfides in humans. Stable modification of tissue proteins by D-PEN may also be involved in the mode of action of D-PEN in rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2565212

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

1.  D-penicillamine metabolism: the role of transformation in blood plasma.

Authors:  D A Joyce; B R Murphy
Journal:  Agents Actions       Date:  1990-11

2.  Influence of barrier-crossing limitations on the amount of macromolecular drug taken up by its target.

Authors:  A Aubrée-Lecat; M C Duban; S Demignot; M Domurado; P Fournié; D Domurado
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

3.  A western blot approach to detection of human plasma protein conjugates derived from D-penicillamine.

Authors:  C A Laycock; M J Phelan; R C Bucknall; J W Coleman
Journal:  Ann Rheum Dis       Date:  1994-04       Impact factor: 19.103

4.  D-penicillamine and D-penicillamine-protein disulphide in plasma and synovial fluid of patients with rheumatoid arthritis.

Authors:  D A Joyce; R O Day
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.